$0.49
8.02% today
Nasdaq, Sep 04, 04:19 pm CET
ISIN
US8006771062
Symbol
SGMO

Sangamo Therapeutics, Inc. Stock price

$0.53
-0.00 0.19% 1M
-0.39 41.99% 6M
-0.49 47.65% YTD
-0.28 34.01% 1Y
-5.00 90.34% 3Y
-9.55 94.70% 5Y
-6.10 91.95% 10Y
-3.50 86.75% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
-0.01 1.00%
ISIN
US8006771062
Symbol
SGMO
Industry

Key metrics

Basic
Market capitalization
$161.1m
Enterprise Value
$122.8m
Net debt
positive
Cash
$38.3m
Shares outstanding
272.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.0 | 2.3
EV/Sales
1.5 | 1.8
EV/FCF
negative
P/B
8.2
Financial Health
Equity Ratio
22.4%
Return on Equity
-430.1%
ROCE
-125.9%
ROIC
-153.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$81.7m | $70.1m
EBITDA
$-58.4m | $-55.4m
EBIT
$-62.8m | $-72.4m
Net Income
$-64.6m | $-82.4m
Free Cash Flow
$-36.2m
Growth (TTM | estimate)
Revenue
540.4% | 21.2%
EBITDA
74.8% | 40.4%
EBIT
74.0% | 26.2%
Net Income
78.3% | 15.9%
Free Cash Flow
79.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-71.4% | -79.1%
EBIT
-76.9%
Net
-79.1% | -117.6%
Free Cash Flow
-44.3%
More
EPS
$-0.3
FCF per Share
$-0.1
Short interest
5.3%
Employees
183
Rev per Employee
$320.0k
Show more

Is Sangamo Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Sangamo Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Sangamo Therapeutics, Inc. forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a Sangamo Therapeutics, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Sangamo Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
82 82
540% 540%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 40 40
33% 33%
49%
- Research and Development Expense 105 105
46% 46%
128%
-58 -58
75% 75%
-71%
- Depreciation and Amortization 4.47 4.47
55% 55%
5%
EBIT (Operating Income) EBIT -63 -63
74% 74%
-77%
Net Profit -65 -65
78% 78%
-79%

In millions USD.

Don't miss a Thing! We will send you all news about Sangamo Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sangamo Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about 3 hours ago
Totality of data supports potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food...
Neutral
Seeking Alpha
27 days ago
Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alexander D. Macrae - CEO, President & Director Gregory Davis - Head of Research & Technology Louise Wilkie - Head of Global Corporate Communications & Investor Relations Nathalie Dubois-Stringfellow - Senior VP & Chief Development Officer Prathyusha Duraibabu - Senior VP, C...
Neutral
GlobeNewsWire
28 days ago
Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval. First clinical site initiated for Phase 1/2 STAND study in chronic neuropathi...
More Sangamo Therapeutics, Inc. News

Company Profile

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

Head office United States
CEO Alexander Macrae
Employees 183
Founded 1995
Website www.sangamo.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today